Your browser doesn't support javascript.
loading
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Wallace, Daniel J; Furie, Richard A; Tanaka, Yoshiya; Kalunian, Kenneth C; Mosca, Marta; Petri, Michelle A; Dörner, Thomas; Cardiel, Mario H; Bruce, Ian N; Gomez, Elisa; Carmack, Tara; DeLozier, Amy M; Janes, Jonathan M; Linnik, Matthew D; de Bono, Stephanie; Silk, Maria E; Hoffman, Robert W.
Afiliação
  • Wallace DJ; Division of Rheumatology, Cedars-Sinai Medical Center, University of California at Los Angeles, Los Angeles, CA, USA. Electronic address: danielwallac@gmail.com.
  • Furie RA; Division of Rheumatology, Zucker School of Medicine at Hofstra, Northwell, New York, NY, USA.
  • Tanaka Y; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Kalunian KC; Division of Rheumatology, University of California at San Diego School of Medicine, La Jolla, CA, USA.
  • Mosca M; Division of Rheumatology, University of Pisa, Pisa, Italy.
  • Petri MA; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Dörner T; Division of Rheumatology, Charite Universitätsmedizin Berlin, Berlin, Germany.
  • Cardiel MH; Centro de Investigación Clínica de Morelia SC, Morelia, México.
  • Bruce IN; Arthritis Research UK Centre for Epidemiology, Faculty of Biology, Medicine and Health, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • Gomez E; Eli Lilly and Company, Indianapolis, IN, USA.
  • Carmack T; Eli Lilly and Company, Indianapolis, IN, USA.
  • DeLozier AM; Eli Lilly and Company, Indianapolis, IN, USA.
  • Janes JM; Eli Lilly and Company, Indianapolis, IN, USA.
  • Linnik MD; Lilly Biotechnology Center, San Diego, CA, USA.
  • de Bono S; Eli Lilly and Company, Indianapolis, IN, USA.
  • Silk ME; Eli Lilly and Company, Indianapolis, IN, USA.
  • Hoffman RW; Eli Lilly and Company, Indianapolis, IN, USA.
Lancet ; 392(10143): 222-231, 2018 07 21.
Article em En | MEDLINE | ID: mdl-30043749
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite / Sulfonamidas / Azetidinas / Exantema / Inibidores de Janus Quinases / Lúpus Eritematoso Sistêmico Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2018 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite / Sulfonamidas / Azetidinas / Exantema / Inibidores de Janus Quinases / Lúpus Eritematoso Sistêmico Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2018 Tipo de documento: Article País de publicação: Reino Unido